Radiance Biopharma Showcases First‑in‑Class c‑MET/EGFR Bispecific Nano ADC at Leading Global ADC Conference

Introduction of a Differentiated Bispecific Nano ADC Positioned to Compete in Major Global Oncology Markets BOSTON, MA, ...

Osimertinib ± Savolitinib in MET-EGFR NSCLC Trial

NSCLC remains the leading cause of cancer-related mortality worldwide, with EGFR mutations being a critical driver in approximately 10-15% of lung adenocarcinomas in Western populations, and up to 40% ...
Pharmaceutical Technology on MSN

J&J’s Rybrevant Faspro gains FDA approval for new dosing in NSCLC

The therapy dosing provides clinical outcomes consistent with those of the earlier approved bi-weekly subcutaneous regimen.
MPR

Rybrevant Faspro Monthly Dosing Approved for EGFR-Mutated NSCLC

Rybrevant Faspro is a subcutaneous co-formulation of amivantamab, a bispecific EGFR-directed and MET receptor-directed antibody, and hyaluronidase.
ascopubs.org

Phase 1 study of BDTX-1535, an oral 4th generation covalent EGFR inhibitor, in patients with recurrent glioblastoma: Preliminary dose escalation results.

Interim report of a phase 2 study of sonodynamic therapy (SDT) using SONALA-001 together with MR-guided low-intensity focused ultrasound (MRgFUS) in children with diffuse intrinsic pontine glioma ...
CURE

ASCO Updates First-Line Treatment for Stage 4 EGFR Lung Cancer

Patients with stage 4 lung cancer and EGFR mutations may benefit from combination therapies that improve disease control. The American Society of Clinical Oncology (ASCO) released updated treatment ...

J INTS BIO Reports Fourth-Generation EGFR Inhibitor JIN-A02 in Clinical Cancer Research

J INTS BIO, Inc. announced that research findings on its investigational fourth-generation EGFR tyrosine kinase inhibitor (TKI), JIN-A02, have been published in Clinical Cancer Research, a leading ...
GlobalData on MSN

Novartis reports final data of ALIGN trial in IgAN

A total of 340 biopsy-confirmed IgAN patients were randomised to daily oral Vanrafia or a placebo for approximately 132 weeks.

EGFR-NSCLC Market to Observe Stunning Growth at a CAGR of 9.6% During the Forecast Period (2025-2034) | DelveInsight

NSCLC Market Insights report includes a comprehensive understanding of current treatment practices, EGFR-NSCLC emerging drugs, market share of individual therapies, and current and forecasted market ...
Healio

Population-based eGFR data may help identify patients at risk for kidney failure earlier

Identifying population-based eGFR distributions may help to identify patients at risk for developing chronic kidney disease earlier, according to study data published in Kidney International. More ...

Cognitive impairment risk increased with severity of chronic kidney disease

For patients with chronic kidney disease (CKD), severity of CKD is associated with an increased incidence of cognitive ...
Medscape

Low eGFR Rates Not Associated With DKA Risk in T1D

In unadjusted analysis, rates of DKA among individuals with an eGFR between 30 and 90 mL/min/1.73 m 2 showed no statistical difference compared with those with an eGFR between 90 and 120 mL/min/1.73 m ...